RxDoctor Payments Data

John Thomson, MD

Family Medicine · Woodland, CANPI 1528167293

Payments from drug & device makers

$258,514in general payments, 2019–2025

Across 323 payments — averaging $800.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$212K
  • Johnson & Johnson$46K
  • Tandem Diabetes Care, Inc.$291
  • Dexcom, Inc.$211
  • Janssen Scientific Affairs, LLC$125
  • Boehringer Ingelheim$89
  • plus $340 from 6 others

What the payments were for

  • Consulting fees$5,9062%
  • Speaking & faculty fees$234,43691%
  • Travel & lodging$11,2604%
  • Food & beverage$6,8683%
  • Education$440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,514 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$72,361
Medicare patients
141
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide289$363,490
JardianceEmpagliflozin209$215,621
EliquisApixaban64$63,410
JanuviaSitagliptin Phosphate56$53,525
Tresiba Flextouch U-100Insulin Degludec77$45,820
TrulicityDulaglutide33$43,866
RybelsusSemaglutide30$31,754
InvokanaCanagliflozin17$16,181
MounjaroTirzepatide15$14,764
Tresiba Flextouch U-200Insulin Degludec11$12,197
TradjentaLinagliptin13$8,735
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen223$8,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,765
Qvar RedihalerBeclomethasone Dipropionate13$5,018
Novolog FlexpenInsulin Aspart29$3,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$211,508$395,244319 claims
Boehringer IngelheimJardiance, Tradjenta$89$224,356222 claims
Lilly USA, LLCTrulicity, Mounjaro$72$58,63048 claims
Johnson & JohnsonInvokana$45,951$16,18117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Woodland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →